North East and North Cumbria Formulary


	North East and North Cumbria ICS Formulary

Search

Results

Looking for Alemtuzumab found 7 matches

Open monograph to display formulary status		BNF Category
	Alemtuzumab	Malignant disease and immunosuppression - Anti-lymphocyte monoclonal antibodies - 08.02.03
	Anakinra (Kineret®)	Musculoskeletal and joint diseases - Cytokine modulators - 10.01.03
	Bendamustine	Malignant disease and immunosuppression - Alkylating drugs - 08.01.01
	Rituximab	Malignant disease and immunosuppression - Anti-lymphocyte monoclonal antibodies - 08.02.03

Links

Link to Drug Section

Link to document

MHRA Drug Safety Update (Feb 2020): Lemtrada▼ (alemtuzumab): updated restrictions and strengthened monitoring requirements following review of serious cardiovascular and immune-mediated reactions (08.02.03)

MHRA Drug Safety Update (May 2019): Lemtrada (alemtuzumab) and serious cardiovascular and immune- mediated adverse reactions: new restrictions to use and strengthened monitoring requirements (08.02.03)

NICE TA312: Alemtuzumab for relapsing‑remitting multiple sclerosis (08.02.03)